0.961  0.019 (1.96%)		08-21 16:00
Open: 0.947 High: 0.961 Volume: 105,801		Pre. Close: 0.9425 Low: 0.9426 Market Cap: 46(M)

Short term
Mid term
Targets	6-month :	1.23	1-year :	1.44
Resists	First :	1.05	Second :	1.23
Pivot price	0.95
Supports	First :	0.93	Second :	0.85
MAs	MA(5) :	0.92	MA(20) :	0.94
	MA(100) :	1.27	MA(250) :	2.07
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	52.9	D(3) :	39.1
RSI	RSI(14): 46.7
52-week	High :	4.98	Low :	0.85

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ FLNA ] has closed below upper band by 46.7%. Bollinger Bands are 50.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.96 - 0.97	0.97 - 0.97
Low:	0.93 - 0.94	0.94 - 0.94
Close:	0.95 - 0.96	0.96 - 0.97

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Thu, 20 Aug 2026
Filana (FLNA) Earnings Snapshot: The EPS Result Is Above Expectation in Latest Trading; After Results: The Market Price Declines 3.72% for the Current Session - Margin Compression Risk - vinanet.vn

Wed, 12 Aug 2026
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - TradingView

Tue, 04 Aug 2026
Filana Therapeutics (FLNA) Slides 3.3% to $1.00 as Small-Cap Biotech Approaches Key Support - Risk Reversal - vinanet.vn

Mon, 03 Aug 2026
Weekly Recap: FDA clinical hold on TSC trial and Q2 2026 cash $82.7M - TradingView

Wed, 29 Jul 2026
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update - Yahoo Finance

Thu, 07 May 2026
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	48 (M)
Shares Float	47 (M)
Held by Insiders	2 (%)
Held by Institutions	28.6 (%)
Shares Short	6,240 (K)
Shares Short P.Month	6,580 (K)

EPS	-0.88
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.32
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-5.6 %
Return on Equity (ttm)	-55.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.33
Sales Per Share	0
EBITDA (p.s.)	-0.21
Qtrly Earnings Growth	0 %
Operating Cash Flow	-29 (M)
Levered Free Cash Flow	6 (M)

PE Ratio	-1.11
PEG Ratio	1.6
Price to Book value	0.72
Price to Sales	0
Price to Cash Flow	-1.62

Dividend	5.25
Forward Dividend	0
Dividend Yield	546.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.